Advertisement

Topics

Silence Therapeutics issues intellectual property claim in the UK which could see its European patent protection extended on certain products

11:39 EDT 3 Jul 2017 | Proactive Investors

Silence Therapeutics PLC (LON:SLN) has issued an intellectual property claim in the UK High Courts of Justice against Alnylam UK Ltd, Alnylam Pharmaceuticals Inc, and The Medicines Co UK Ltd which could see its European patent protection extended. The claim asks the court to determine whether Silence is entitled to supplementary protection certificates on several late stage Alnylam products, which include Patisiran, Fitusiran, Givosiran and Inclisiran, which were developed with partner, The Medicines Co. WATCH: Silence Therapeutics 'honour-bound' to attack and defend their patents - CEO Ali Mortazavi Silence said it could result in the extension of its European patent protection on these products. Supplementary protection certificates are intellectual property rights which can give up to five years of exclusivity after a patent expires. The company said it was "committed to defending its intellectual property" and to securing the appropriate value for the intellectual property, and maintained that it "will act to enforce its patent estate as necessary". READ: Silence Therapeutics eyes late stage payments as it widens patent net for gene silencing tech Silence Therapeutics’ chief executive Ali Mortazavi, said the company considers "potential licences under our patent estate could have a significant financial effect relative to the current market capitalisation of Silence. As such, we consider the commencement of this process to be the next step in realising this value". Silence added that, separately it is also "actively continuing to uphold its patent estate in other global regions". In May, the biotech firm said that it will be issued with a US patent to further protect its chemical modification technology. In late afternoon trading, Silence were 1.9%, or 1.75p higher at 96.0p.

Original Article: Silence Therapeutics issues intellectual property claim in the UK which could see its European patent protection extended on certain products

NEXT ARTICLE

More From BioPortfolio on "Silence Therapeutics issues intellectual property claim in the UK which could see its European patent protection extended on certain products"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...